EcoDrugPlus

Tyrosinase

Ensembl ID : ENSBSLG00000016234
Gene Symbol: TYR
3 Cross references
203 Possible Orthologues:

Tyrosinase

Ensembl ID : ENSBSLG00000003149
Gene Symbol: TYR
3 Cross references
196 Possible Orthologues:

Tyrosine Hydroxylase

Ensembl ID : ENSBSLG00000005632
Gene Symbol: TH
3 Cross references
188 Possible Orthologues:

Tyrosine Kinase 2

Ensembl ID : ENSBSLG00000017161
Gene Symbol: TYK2
3 Cross references
196 Possible Orthologues:

Tyrosine Kinase With Immunoglobulin Like And Egf Like Domains 1

Ensembl ID : ENSBSLG00000007924
Gene Symbol: TIE1
3 Cross references
207 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSBSLG00000007973
Gene Symbol: LOC114863191
3 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Jak2-Like

Ensembl ID : ENSBSLG00000012598
Gene Symbol: LOC114866765
3 Cross references
198 Possible Orthologues:

Tyrosine-Protein Kinase Lyn-Like

Ensembl ID : ENSBSLG00000021246
Gene Symbol: LOC114844557
3 Cross references
196 Possible Orthologues:

Tyrosine-Protein Kinase Srk2-Like

Ensembl ID : ENSBSLG00000021726
Gene Symbol: LOC114858706
3 Cross references
160 Possible Orthologues:

Tyrosine-Protein Kinase Syk-Like

Ensembl ID : ENSBSLG00000002492
Gene Symbol: LOC114866931
3 Cross references
202 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSBSLG00000017694
Gene Symbol: LOC114849057
3 Cross references
192 Possible Orthologues:

Tyrosine-Protein Kinase Yes

Ensembl ID : ENSBSLG00000026576
Gene Symbol: LOC114844103
3 Cross references
197 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).